0

United States Multiple Myeloma Market Size & Forecast 2025-2033

 2 days ago
source link: https://www.renub.com/united-states-multiple-myeloma-market-p.php
Go to the source link to view the article. You can view the picture content, updated content and better typesetting reading experience. If the link is broken, please click the button below to view the snapshot at that time.
neoserver,ios ssh client

The United States Multiple Myeloma Market is projected to grow from US$ 6.56 billion in 2024 to US$ 12.04 billion by 2033, at a strong CAGR of 6.99% during 2025–2033. Rising incidence rates, an aging population, and advances in targeted therapies, immunotherapies, and combination treatments are fueling growth, improving patient outcomes, and sustaining market expansion.

Market Overview

Multiple myeloma is a malignancy of bone marrow plasma cells, accounting for around 10% of all hematologic cancers in the U.S. The disease primarily affects individuals over 65, and with the American Cancer Society reporting thousands of new cases annually, the burden is expected to increase as the population ages. The availability of advanced oncology facilities and a robust healthcare system supports the quick adoption of new therapies.

Growth Drivers

Aging Population & Rising Incidence: Older adults are at higher risk, creating long-term demand.

Immunotherapy & Targeted Therapies: Proteasome inhibitors, monoclonal antibodies, and CAR T-cell therapy are transforming outcomes.

FDA Approvals & Clinical Trials: Accelerated review processes and breakthrough designations speed up innovation.

Key Challenges

High Costs: CAR T-cell and antibody-based therapies can cost hundreds of thousands per year.

Access Inequality: Rural and underserved areas face barriers in reaching advanced oncology care.

Market by States

California: Strong biotech ecosystem, leading cancer research centers.

Texas: Large, diverse population with expanding oncology infrastructure.

New York: Renowned cancer institutes like Memorial Sloan Kettering.

Florida: Large elderly population driving demand for advanced treatments.

Major Players

Novartis AG, AbbVie Inc., Sanofi, Johnson & Johnson, Pfizer Inc., Takeda, Bristol-Myers Squibb, Baxter International

Conclusion

With rising cases, strong clinical pipelines, and supportive regulatory frameworks, the U.S. Multiple Myeloma Market is expected to remain on a robust growth path. However, balancing affordability with access will be critical for ensuring equitable benefits from medical innovation.


Recommend

About Joyk


Aggregate valuable and interesting links.
Joyk means Joy of geeK